HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Recruiting · NCT07240766 · Registry updated 2026-02-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation | Borderline Resectable Pancreatic Adenocarcinoma | Recruiting | Phase 2 | 2026-02-13 | NCT07240766 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhejiang University | 194 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| First Affiliated Hospital of Zhejiang University Schlool of Medicine | Hangzhou | China | 4 |
| the First Affiliated Hospital of Zhejiang University, School of Medicine | Hangzhou | China | 1 |